An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis
نویسندگان
چکیده
Onychomycosis is a fungal nail infection which is relatively common and difficult to treat. Treatment modalities include nail avulsion, surgical debridement and combination therapy with oral and topical antifungal drugs. In spite of a host of available drugs, clinical cure rates remain discouraging. Drug toxicities, prolonged regimens, lack of patient compliance, and high keratin affinity of drugs are all contributive factors. Efinaconazole is a novel topical triazole antifungal agent that has shown excellent in vitro activity against both dermatophyte and non-dermatophyte fungi causing onychomycosis. This study presents the in vitro susceptibility profiles of 44 common non-dermatophyte fungi against efinaconazole and itraconazole, another azole drug used in the treatment of onychomycosis.
منابع مشابه
Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Onychomycosis is a common fungal nail infection in adults that is difficult to treat. The in vitro antifungal activity of efinaconazole, a novel triazole antifungal, was evaluated in recent clinical isolates of Trichophyton rubrum, Trichophyton mentagrophytes, and Candida albicans, common causative onychomycosis pathogens. In a comprehensive survey of 1,493 isolates, efinaconazole MICs against ...
متن کاملSuccessful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole.
Paecilomyces lilacinus, also known as Purpureocillium lilacinum, is a non-dermatophyte mold found in the soil and used as nematocide for crops. P. lilacinus can cause rare opportunistic infections in humans ranging from endocarditis, keratitis, to onychomycosis with significant resistance to conventional antifungals. There are only two cases of onychomycosis caused by P. lilacinus reported in t...
متن کاملEfinaconazole in the treatment of onychomycosis
Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mecha...
متن کاملComparison of in vitro antifungal activities of efinaconazole and 1 currently available antifungal agents against a variety of pathogenic 2 fungi associated with onychomycosis 3 4
Comparison of in vitro antifungal activities of efinaconazole and 1 currently available antifungal agents against a variety of pathogenic 2 fungi associated with onychomycosis 3 4 William J. Jo Siu, Yoshiyuki Tatsumi, Hisato Senda, Radhakrishnan Pillai, Takashi 5 Nakamura, Daisuke Sone, Annette Fothergill 6 7 Dow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America 8 LLC...
متن کاملCharacterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain.
Due to the increase of choices relative to antifungals, there is a need to improve the standardization of in vitro methods used to determine the antifungal susceptibility of fungal pathogens. Our study evaluated the in vitro susceptibility of filamentous fungi isolated from patients with toenail onychomycosis against itraconazole, ciclopirox, eberconazole, fluconazole and terbinafine. The minim...
متن کامل